1. Figure 4 New PET radiotracers in lymphoma
Figure 4 | New PET radiotracers in lymphoma. a–f | Synchronous images of a patient with diffuse large B-cell lymphoma of the CNS of the germinal centre B-cell (GCB)-like phenotype. a | Contrast-enhanced coronal MRI of a patient with a midline lymphomatous mass. b | Coronal PET image showing physiological FDG–PET uptake in the CNS, which reduces the accuracy of lesion detection. c–f | Multiple short-interval relapses (subsequent to complete responses on both MRI and [18F]fluoromethylcholine (FCH)–PET, images not shown), note the concordance of MRI and FCH–PET images in terms of lesion detection. g–i | Synchronous images of a patient with lymphoblastic lymphoma. g | Posterior coronal contrast-enhanced MRI image with diffuse dural infiltration and abnormal marrow signal. h | Fused FCH-PET–CT coronal image demonstrating abnormal dural tracer uptake (arrow). i | Fused FCH-PET–CT maximum intensity projection demonstrating diffuse marrow uptake (arrow). FCH–PET did not demonstrate any substantial prognostic power for response duration; efficacy of FCH–PET for leptomeningeal disease has not been evaluated. No published studies evaluating the performance of FCH–PET exist for patients with CNS lymphoma. Image series courtesy of B. Sharma and N. Tunariu, The Royal Marsden, London, UK.
Cunningham, J. et al. (2017) Evolution of lymphoma staging and response evaluation: current limitations and future directions
Nat. Rev. Clin. Oncol. doi: /nrclinonc